#### EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES Vienna, Austria 22 – 25 April 2017

# Implementation of rejection criteria for stool culture: a ballad of loss and gains?

L. CATTOIR <sup>1</sup>, P. VANDECANDELAERE <sup>2</sup>, R. CARTUYVELS <sup>3</sup>, G. COPPENS <sup>4</sup>, H. DE BEENHOUWER <sup>5</sup>, J. FRANS <sup>6</sup>, W. LAFFUT <sup>7</sup>, A. VAN DEN ABEELE <sup>1</sup>. On behalf of the BILULU Study Group

<sup>1</sup> AZ Sint-Lucas, Gent, <sup>2</sup> Jan Yperman Ziekenhuis, Ieper, <sup>3</sup> Virga Jesseziekenhuis, Hasselt, <sup>4</sup> Ziekenhuis Oost-Limburg, Genk, <sup>5</sup> Onze-Lieve-Vrouw Ziekenhuis, Aalst, <sup>6</sup> Imelda Ziekenhuis, Bonheiden, Belgium, <sup>7</sup> Heilig Hartziekenhuis, Lier, Belgium,

### INTRODUCTION

Stool culture is time consuming and positivity rate in resource-rich settings is low. To gain efficiency and reduce costs, rejection criteria are implemented which allow to reduce the number of fecal samples cultured, without missing clinically relevant enteropathogens. We retrospectively evaluated the impact of two rejection criteria recommended by guidelines<sup>1,2</sup>:

(1) rejection of samples from patients hospitalized >3 days (3DAY)

(2) rejection of solid stool samples (SOLID)

#### **METHODS**

We reviewed the results of nonduplicate stool cultures for gastrointestinal pathogens except Clostridium difficile performed in 2015 in 7 Belgian secondary care hospitals, the BILULU study group.

**3DAY** was applied to the results of 7 labs (16476 samples).



SOLID was applied to the results of 6 of 7 labs (14102 samples).

Medical records of a subset of 50 patients with rejected samples for each of both criteria, but positive for a bacterial pathogen, were reviewed for gastrointestinal symptoms and patient management.

## RESULTS

Reduction of total number of samples for culture: Percentage of pathogens missed: Gastro-intestinal symptoms

| Gastro-intestinal symptoms  |                   |                   | -               |               | 38/50 patients         |               | 46/50 patients |              |
|---|-------------------|-------------------|-----------------|---------------|------------------------|---------------|----------------|--------------|
| Treatment with antibiotics  |                   |                   | -               |               | 9/50 patients          |               | 6/50 patients  |              |
|   |                   |                   |                 |               | Number of samples with |               |                |              |
|   | Number of samples | Any pathogen      | Salmonella spp. | Shigella spp. | Campylobacter spp.     | Yersinia spp. | Aeromonas spp. | Other genera |
| Length of hospital stay   |                   |                   |                 |               |                        |               |                |              |
| ≤3 days   | 11233 (68%)       | 1059 (9,4%)       | 181 (1,6%)      | 11 (0,10%)    | 606 (5,4%)             | 33 (0,29%)    | 185 (1,6%)     | 68 (0,61%)   |
| >3 days ( <b>3DAY</b> )   | 5243 (32%)        | <b>110</b> (2,1%) | 13 (0,25%)      | 1 (0,02%)     | 34 (0,65%)             | 9 (0,17%)     | 40 (0,76%)     | 20 (0,38%)   |
| All samples   | 16476             | 1169 (7,1%)       | 194 (1,2%)      | 12 (0,07%)    | 640 (3,9%)             | 42 (0,25%)    | 225 (1,4%)     | 88 (0,53%)   |
| Consistency   |                   |                   |                 |               |                        |               |                |              |
| Solid (SOLID)   | 2781 (20%)        | <b>86</b> (3,1%)  | 9 (0,32%)       | 0 (0%)        | 43 (1,5%)              | 6 (0,22%)     | 10 (0,36%)     | 19 (0,68%)   |
| Non-solid   | 11321 (80%)       | 910 (8,0%)        | 157 (1,4%)      | 12 (0,11%)    | 518 (4,6%)             | 23 (0,20%)    | 160 (1,4%)     | 64 (0,57%)   |
| All samples   | 14102             | 996 (7,1%)        | 166 (1,2%)      | 12 (0,09%)    | 561 (4,0%)             | 29 (0,21%)    | 170 (1,2%)     | 83 (0,59%)   |
|   |                   |                   |                 |               |                        |               |                |              |
|   |                   |                   |                 |               |                        |               |                |              |
| CUNCLUSION  |                   |                   |                 |               |                        |               |                |              |
| Implementation of 3DAY and SOLID rejection criteria for stool culture reduces sample number with ≥20% but impairs the yield |                   |                   |                 |               |                        |               |                |              |

ALL SAMPLES

0%

0%

**3DAY** 

32%

9.7%

enteropathogens with 9,7% and 8,5% respectively. Using 3DAY, pathogens are missed due to **delayed sampling** in patients lacking manifest symptoms at presentation or logistical issues. Implementing SOLID excludes patients with intermittent diarrhea. In the group of missed pathogens, both established and emerging pathogens are represented. The clinical relevance is supported by the fact that most patients had gastrointestinal symptoms, for which some needed antibiotic treatment.

<sup>1</sup> Clinical Microbiology Procedures Handbook, 4<sup>th</sup> Ed. 2016, Leber AL (Eds.), volume 1, ASM Press Washington DC. <sup>2</sup> Humphries RM, Linscott AJ. Laboratory diagnosis of bacterial gastroenteritis. Clin Microbiol Rev. 2015 Jan;28(1):3-31.



**SOLID** 

20%

8,5%

